share_log

JOLT HEALTH INC. ANNOUNCES NEW CEO AND DIRECTOR TO LEAD BIOTECHNOLOGY, HEALTHCARE AND AI INITIATIVES

JOLT HEALTH INC. ANNOUNCES NEW CEO AND DIRECTOR TO LEAD BIOTECHNOLOGY, HEALTHCARE AND AI INITIATIVES

JOLT HEALTH INC.宣佈新任首席執行官兼董事將領導生物技術、醫療保健和人工智能計劃
GlobeNewswire ·  2023/06/02 10:00

VANCOUVER, BC, CANADA, June 02, 2023 (GLOBE NEWSWIRE) -- Jolt Health Inc. ("JOLT" and or "The Company")(CSE: JOLT) (FSE: G1Q0) (previously Love Pharma), the Company, is thrilled to announce that Mr. Gerald Tritt has joined the Company as a Director and CEO. Mr. Tritt is a seasoned entrepreneur with a proven track record of success in the public markets and vast experience in various industries.

加拿大溫哥華,卑詩省,2023年6月2日(環球通訊社)--Jolt Health Inc.(以下簡稱“Jolt”和/或“公司”)(CSE:Jolt)(法蘭克福證券交易所股票代碼:G1Q0)(原Love Pharma),公司欣喜地宣佈,Gerald Tritt先生已加盟公司,擔任董事總裁兼首席執行官。特裡特是一位經驗豐富的企業家,在公開市場上取得了成功,並在各個行業擁有豐富的經驗。

As an early stage investor, Mr. Tritt has co-founded and co-owned several restaurant concepts, including the one of Canada's most prominent fast food chains, where he served as CEO. He has also consulted with international biotech companies in the health and wellness sector on their logistics and organizational structure, leveraging his extensive knowledge of e-commerce and online presence development to expand their reach during the covid-19 pandemic.

作為一名早期投資者,特裡特曾聯合創立並共同擁有多家餐廳,其中包括他擔任首席執行長的加拿大最著名的速食連鎖店之一。他還就物流和組織結構與健康領域的國際生物技術公司進行了諮詢,利用他在電子商務和在線業務發展方面的廣泛知識,在新冠肺炎疫情期間擴大了它們的覆蓋範圍。

Mr. Tritt has held senior management positions in both national and international hospitality groups, providing him with valuable leadership and operations skills that will prove essential in his role as CEO of Jolt Health. As an investor in multiple startups across different industries, he brings firsthand capital markets experience, an extensive network, corporate governance and strong private equity background to the company.

特裡特先生曾在國內和國際酒店集團擔任高級管理職位,這為他提供了寶貴的領導和運營技能,這些技能將被證明是他擔任Jolt Health首席執行官所必需的。作為不同行業多家初創公司的投資者,他為公司帶來了第一手的資本市場經驗、廣泛的網路、公司治理和強大的私募股權背景。

"We are delighted to welcome Mr. Tritt to the Jolt Health team as our new CEO and Director," Said Zachary Stadnyk, the Company's outgoing CEO. "His diverse background in various industries, exceptional leadership skills, and his vast experience in the public markets make him the perfect candidate to lead Jolt Health's new vision in Healthcare, Biotechnology and AI. We believe that his addition to the team will be instrumental in taking the company to new heights and we look forward to the future under his leadership."

即將離任的董事首席執行官扎卡裡·斯塔德尼克說:“我們很高興地歡迎特裡特先生加入Jolt Health團隊,擔任我們的新任首席執行官兼首席執行官。他在各個行業的不同背景、非凡的領導技能以及在公開市場的豐富經驗使他成為領導Jolt Health在醫療保健、生物技術和人工智慧領域新願景的完美人選。我們相信,他加入團隊將有助於將公司推向新的高度,我們期待著在他的領導下的未來。

Mr. Tritt stated, "I am thrilled to join Jolt Health and lead the company's ambitious initiatives. I believe that the combination of Jolts's existing expertise and resources, together with my experience and network, will enable us to develop innovative solutions and exciting investment opportunities. I am motivated about the opportunity to create value for our shareholder and to help Jolt Health achieve its full potential."

特裡特先生說:“我很高興能加入Jolt Health並領導公司雄心勃勃的計劃。我相信,Jolts現有的專業知識和資源,加上我的經驗和網路,將使我們能夠開發創新的解決方案和令人興奮的投資機會。我對為我們的股東創造價值的機會充滿動力,並幫助Jolt Health充分發揮其潛力。”

The appointment of Mr. Tritt as CEO and Director is effective immediately, and he will work closely with the Jolt Health team to develop and execute the Company's strategic plan.

任命特裡特先生為董事首席執行官立即生效,他將與Jolt Health團隊密切合作,制定和執行公司的戰略計劃。

On behalf of the board of directors and management, the Company's wishes to thank Mr. Stadnyk for his instrumental role in publicly listing, financing and growing the company thus far. He will remain a close advisor to the company on corporate finance and acquisition related matters going forward.

本公司謹代表董事會和管理層感謝Stadnyk先生迄今為止在公司上市、融資和發展方面發揮的重要作用。未來,他仍將是公司在公司融資和收購相關事宜上的密切顧問。

Zachary Stadnyk, CEO and Director

董事首席執行官扎克裡·斯塔德尼克

About Jolt Health Inc.

關於Jolt Health Inc.

Jolt Health Inc. (CSE – JOLT) is a leading healthcare, biotechnology and artificial intelligence company dedicated to revolutionizing global healthcare. The company currently holds exclusive licenses for innovative therapeutic and pharmaceutical products throughout Europe, the UK, and North America. The company is committed to transforming the industry through research, collaboration, and technological advancement, sharping the future of healthcare worldwide.

Jolt Health Inc.(CSE-Jolt)是一家領先的醫療保健、生物技術和人工智慧公司,致力於給全球醫療保健帶來革命性的變化。該公司目前在歐洲、英國和北美擁有創新治療和製藥產品的獨家許可證。該公司致力於通過研究、合作和技術進步來改變行業,提升全球醫療保健的未來。

For further information, please contact:

如需更多資訊,請聯繫:

Investor Relations

投資者關係

Telephone: 1 (604) 343-2977

電話:1(604)343-2977

E-mail: info@jolt-health.com

電子郵件:info@jolt-Health.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Certain statements contained in this release may constitute "forward–looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing, and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

本新聞稿中包含的某些陳述可能構成“前瞻性陳述”或“前瞻性資訊”(統稱為“前瞻性資訊”),因為這些術語在1995年的“私人證券訴訟改革法”和類似的加拿大法律中使用。這些陳述與未來的事件或未來的表現有關。使用“可能”、“打算”、“預期”、“相信”、“將”、“預計”、“估計”、“預期”以及與非歷史事實有關的類似表述和陳述,旨在識別前瞻性資訊,並基於公司對此類未來事件的結果和時機的當前信念或假設。未來的實際結果可能會有很大不同。特別是,本新聞稿包含與公司業務、融資和某些公司變化有關的前瞻性資訊。本新聞稿中包含的前瞻性資訊是截至本新聞稿發佈之日的資訊,公司沒有義務因新資訊、未來事件或其他原因而更新或修改任何前瞻性資訊,除非適用的證券法要求這樣做。由於本文包含的風險、不確定性和假設,投資者不應過度依賴前瞻性資訊。上述陳述明確表示,本文中包含的任何前瞻性資訊都是合格的。

CONTACT: Investor Relations Jolt Health Inc.  1 (604) 343-2977 info@jolt-health.com 
聯繫方式:投資者關系部jolt Health Inc.1(604)343-2977

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論